

# Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy

Naseema Gangat,\* Rimal Ilyas,\* Isla M. Johnson, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek Mangaonkar, Mark R Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani and Ayalew Tefferi

Division of Hematology, Mayo Clinic, Rochester, MN, USA

*\*NG and RI contributed equally as first authors.*

Correspondence:

N. GANGAT - [gangat.naseema@mayo.edu](mailto:gangat.naseema@mayo.edu).

<https://doi.org/10.3324/haematol.2022.282677>

Supplemental Table 1. Clinical characteristics at time of treatment with venetoclax and hypomethylating agent (HMA) for 103 patients with treatment naïve acute myeloid leukemia stratified by treatment response to venetoclax and HMA

Variables	All patients n=103	Patients with relapsed or refractory disease n=71	Patients without relapse or refractory disease n=32	P-value
Age in years, median (range)	74 (36-92)	74(37-91)	72 (52-86)	0.84
Male, n (%)	69 (67)	50(70)	19 (59)	0.27
AML type, n (%)				
- <i>De novo</i>	64 (62)	43 (61)	23 (72)	0.26
- Secondary or therapy-related	39 (38)	28 (40)	9 (28)	
Hemoglobin, g/dl, median (range)	8.6 (4.8-14)	8.6(5.1-14)	8.6 (4.8-13.6)	0.58
Leukocyte count x 10 <sup>9</sup> /L, median (range)	3.6 (0.1-116)	4.4(0.5-117)	2.9 (0.1-95)	0.79
Platelet count x 10 <sup>9</sup> /L, median (range)	59.5 (7-444)	60(7-444)	52 (9-212)	0.76
Circulating blasts %, median (range)	14 (0-93)	14(0-92)	11 (0-93)	0.39
Bone marrow blasts %, median (range)	48 (2-97)	48(20-95)	40 (2-97)	0.33
2017 ELN cytogenetic risk stratification, n (%)				
-Favorable	5 (5)	0	5 (16)	<b>0.15</b>
-Intermediate	52 (50)	36 (51)	16 (50)	
-Adverse	46 (45)	35 (49)	11 (34)	
Mutations, n (%)				
- <i>TP53</i>	25 (25)	23 (32)	2 (6)	<b>0.002</b>
- <i>ASXL1</i>	18 (18)	12 (17)	6 (19)	0.82
- <i>RUNX1</i>	19 (19)	13 (18)	6 (19)	0.96
- <i>TET2</i>	24 (23)	18 (25)	6 (19)	0.46
- <i>SRSF2</i>	18 (18)	12 (17)	6 (19)	0.82
- <i>IDH1/IDH2</i>	20 (19)	11 (16)	9 (28)	0.23
- <i>NPM1</i>	13 (13)	7 (10)	6 (19)	0.45
- <i>K/NRAS</i>	15 (15)	9 (13)	6 (19)	0.43
- <i>FLT3-ITD</i>	10 (10)	10 (14)	0 (0)	<b>0.005</b>
HMA used, n (%)				
- Azacitidine	39 (38)	26 (36)	13 (41)	0.69
- Decitabine	64 (62)	45 (63)	19 (59)	
Final dose of venetoclax, mg, (median, range)	200 (50-400)	200 (50-400)	200 (100-400)	0.91

ELN- European Leukemia Net